menu
    • menu
    [{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"DecentraNet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Ropocamptide","moa":"Hepatitis B virus membrane","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maxwell Biosciences \/ DecentraNet","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Biosciences \/ DecentraNet"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ropocamptide","moa":"Keratinocyte","graph1":"Podiatry","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ropocamptide

    Menu

    Ropocamptide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Promore Pharma

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Promore Pharma

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropocamptide

                            Therapeutic Area : Podiatry

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds

                            Details : The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).

                            Brand Name : LL-37

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 10, 2022

                            Lead Product(s) : Ropocamptide

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Maxwell Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Maxwell Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropocamptide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : DecentraNet

                            Deal Size : $10.8 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round

                            Details : The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.

                            Brand Name : LL-37

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 10, 2022

                            Lead Product(s) : Ropocamptide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : DecentraNet

                            Deal Size : $10.8 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth